Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Pleural Cavity Tumor Microenvironment: Primary and Metastatic Tumors
share announcement

Pleural Cavity Tumor Microenvironment: Primary and Metastatic Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 16393

Special Issue Editors

Dr. Georgia Karpathiou

E-Mail Website
Guest Editor
Department of Pathology, University Hospital of Saint-Etienne, Hôpital Nord, 42055 CEDEX 2, Saint Etienne, France
Interests: Gynecologic Pathology; Thoracic Pathology; Pleural Disease; Immunopathology; Tumor Microenvironment
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Marios Froudarakis

E-Mail
Guest Editor
Department of Pneumonology and Thoracic Oncology, University Hospital of Saint-Etienne, North Hospital, 42055 CEDEX 2, Saint Etienne, France
Interests: Pleural disease; Thoracic Oncology

Special Issue Information

Dear Colleagues,

Pleural effusion is a major diagnostic and therapeutic problem with more than 1.5 million patients suffering from this condition in the United States every year. Cancer is one of the commonest etiologies of pleural effusion, and both metastatic diseases and primary tumors show poor prognosis and urge for therapeutic advance. Immunotherapy has demonstrated promising results in various forms of cancer, and its utility in pleural diseases is under investigation. Furthermore, basic, and translational studies are trying to elucidate the role of the numerous factors of the tumor microenvironment, like inflammatory cells, vascular bed, extracellular matrix, extracellular vesicles, neural fibers in various forms of cancer, including the pleural cavity, which has unique physiological characteristics.

This Special Issue aims to gather all recent development in the tumor microenvironment of the pleural cavity, in terms of basic and translational science, but also of clinical and therapeutic advance.

Dr. Georgia Karpathiou
Prof. Dr. Marios Froudarakis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mesothelioma
  • inflammation
  • pleural effusion
  • pleural metastases
  • matrix
  • exosomes
  • immunotherapy
  • vascular density
  • fibrosis

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

24 pages, 24783 KiB  
Review
Inflammation of the Pleural Cavity: A Review on Pathogenesis, Diagnosis and Implications in Tumor Pathophysiology
by Georgia Karpathiou, Michel Péoc’h, Anand Sundaralingam, Najib Rahman and Marios E. Froudarakis
Cancers 2022, 14(6), 1415; https://doi.org/10.3390/cancers14061415 - 10 Mar 2022
Cited by 5 | Viewed by 4521
Abstract
Pleural effusions are a common respiratory condition with many etiologies. Nonmalignant etiologies explain most pleural effusions and despite being nonmalignant, they can be associated with poor survival; thus, it is important to understand their pathophysiology. Furthermore, diagnosing a benign pleural pathology always harbors [...] Read more.
Pleural effusions are a common respiratory condition with many etiologies. Nonmalignant etiologies explain most pleural effusions and despite being nonmalignant, they can be associated with poor survival; thus, it is important to understand their pathophysiology. Furthermore, diagnosing a benign pleural pathology always harbors the uncertainty of a false-negative diagnosis for physicians and pathologists, especially for the group of non-specific pleuritis. This review aims to present the role of the inflammation in the development of benign pleural effusions, with a special interest in their pathophysiology and their association with malignancy. Full article
(This article belongs to the Special Issue Pleural Cavity Tumor Microenvironment: Primary and Metastatic Tumors)
►▼ Show Figures

Figure 1

15 pages, 1107 KiB  
Review
Primary Effusion Lymphoma: A Clinicopathologic Perspective
by Diamone A. Gathers, Emily Galloway, Katalin Kelemen, Allison Rosenthal, Sarah E. Gibson and Javier Munoz
Cancers 2022, 14(3), 722; https://doi.org/10.3390/cancers14030722 - 30 Jan 2022
Cited by 9 | Viewed by 4288
Abstract
Primary effusion lymphoma (PEL) is a rare, aggressive B-cell lymphoma that usually localizes to serous body cavities to subsequently form effusions in the absence of a discrete mass. Although some tumors can develop in extracavitary locations, the areas most often affected include the [...] Read more.
Primary effusion lymphoma (PEL) is a rare, aggressive B-cell lymphoma that usually localizes to serous body cavities to subsequently form effusions in the absence of a discrete mass. Although some tumors can develop in extracavitary locations, the areas most often affected include the peritoneum, pleural space, and the pericardium. PEL is associated with the presence of human herpesvirus 8 (HHV8), also called the Kaposi sarcoma-associated herpesvirus (KSHV), with some variability in transformation potential suggested by frequent coinfection with the Epstein-Barr virus (EBV) (~80%), although the nature of the oncogenesis is unclear. Most patients suffering with this disease are to some degree immunocompromised (e.g., Human immunodeficiency virus (HIV) infection or post-solid organ transplantation) and, even with aggressive treatment, prognosis remains poor. There is no definitive guideline for the treatment of PEL, although CHOP-like regimens (cyclophosphamide, doxorubicin, vincristine, and prednisone) are frequently prescribed and, given the rarity of this disease, therapeutic focus is being redirected to personalized and targeted approaches in the experimental realm. Current clinical trials include the combination of lenalidomide and rituximab into the EPOCH regimen and the treatment of individuals with relapsed/refractory EBV-associated disease with tabelecleucel. Full article
(This article belongs to the Special Issue Pleural Cavity Tumor Microenvironment: Primary and Metastatic Tumors)
►▼ Show Figures

Figure 1

20 pages, 1252 KiB  
Review
Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
by Francesca Cersosimo, Marcella Barbarino, Silvia Lonardi, William Vermi, Antonio Giordano, Cristiana Bellan and Emanuele Giurisato
Cancers 2021, 13(22), 5664; https://doi.org/10.3390/cancers13225664 - 12 Nov 2021
Cited by 17 | Viewed by 3556
Abstract
Several studies have reported that cellular and soluble components of the tumor microenvironment (TME) play a key role in cancer-initiation and progression. Considering the relevance and the complexity of TME in cancer biology, recent research has focused on the investigation of the TME [...] Read more.
Several studies have reported that cellular and soluble components of the tumor microenvironment (TME) play a key role in cancer-initiation and progression. Considering the relevance and the complexity of TME in cancer biology, recent research has focused on the investigation of the TME content, in terms of players and informational exchange. Understanding the crosstalk between tumor and non-tumor cells is crucial to design more beneficial anti-cancer therapeutic strategies. Malignant pleural mesothelioma (MPM) is a complex and heterogenous tumor mainly caused by asbestos exposure with few treatment options and low life expectancy after standard therapy. MPM leukocyte infiltration is rich in macrophages. Given the failure of macrophages to eliminate asbestos fibers, these immune cells accumulate in pleural cavity leading to the establishment of a unique inflammatory environment and to the malignant transformation of mesothelial cells. In this inflammatory landscape, stromal and immune cells play a driven role to support tumor development and progression via a bidirectional communication with tumor cells. Characterization of the MPM microenvironment (MPM-ME) may be useful to understand the complexity of mesothelioma biology, such as to identify new molecular druggable targets, with the aim to improve the outcome of the disease. In this review, we summarize the known evidence about the MPM-ME network, including its prognostic and therapeutic relevance. Full article
(This article belongs to the Special Issue Pleural Cavity Tumor Microenvironment: Primary and Metastatic Tumors)
►▼ Show Figures

Figure 1

31 pages, 21753 KiB  
Review
The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review
by Anne-Laure Désage, Georgia Karpathiou, Michel Peoc’h and Marios E. Froudarakis
Cancers 2021, 13(13), 3205; https://doi.org/10.3390/cancers13133205 - 26 Jun 2021
Cited by 16 | Viewed by 3200
Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour with a poor prognosis, associated with asbestos exposure. Nowadays, treatment is based on chemotherapy with a median overall survival of less than two years. This review highlights the main characteristics of the immune [...] Read more.
Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour with a poor prognosis, associated with asbestos exposure. Nowadays, treatment is based on chemotherapy with a median overall survival of less than two years. This review highlights the main characteristics of the immune microenvironment in MPM with special emphasis on recent biological advances. The MPM microenvironment is highly infiltrated by tumour-associated macrophages, mainly M2-macrophages. In line with infiltration by M2-macrophages, which contribute to immune suppression, other effectors of innate immune response are deficient in MPM, such as dendritic cells or natural killer cells. On the other hand, tumour infiltrating lymphocytes (TILs) are also found in MPM, but CD4+ and CD8+ TILs might have decreased cytotoxic effects through T-regulators and high expression of immune checkpoints. Taken together, the immune microenvironment is particularly heterogeneous and can be considered as mainly immunotolerant or immunosuppressive. Therefore, identifying molecular vulnerabilities is particularly relevant to the improvement of patient outcomes and the assessment of promising treatment approaches. Full article
(This article belongs to the Special Issue Pleural Cavity Tumor Microenvironment: Primary and Metastatic Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop